<DOC>
	<DOCNO>NCT02433340</DOCNO>
	<brief_summary>This Phase 2 , multicenter , 24-week , open-label extension ( OLE ) study assess safety tolerability ABT-122 rheumatoid arthritis ( RA ) subject complete Study M12-963 Phase 2 RCT .</brief_summary>
	<brief_title>Phase 2 , Multicenter , Open-Label Extension ( OLE ) Study With ABT-122 Rheumatoid Arthritis Subjects Who Have Completed Preceding M12-963 Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects complete precede Study M12963 ( ABT122 ) RCT study develop discontinuation criterion , define Section 5.4.1 Study M12963 . If female , subject must meet one follow criterion : 1 . Postmenopausal ( define menses least 1 year ) . 2 . Surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) . 3 . Practicing appropriate birth control , time enrollment study least 150 day last dose study drug . Females undergone tubal ligation require agree use second form contraception period time . Male agrees follow one protocolspecified pregnancy avoidance measure , include refrain donate sperm , 150 day post last dose study drug . Subjects must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . Subject judge good health determine Investigator base result medical history , physical examination laboratory profile perform . Pregnant breastfeed female . Ongoing infection Day 1 ( Week 0 ) NOT successfully treat within 14 day . Anticipated requirement receipt live vaccine study participation include 120 day last dose study drug . Current enrollment another investigational study ; exception Study M12963 , require . Consideration Investigator , reason , subject unsuitable candidate receive ABT122 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Safety</keyword>
</DOC>